Patients with psoriasis who show an early response to the biologics risankizumab or guselkumab are more likely to have a long ...

Professor Omar Usmani and Respiratory Effectiveness Group colleagues outline a pragmatic approach to inhaler choice and ...

RPath president Dr Bernie Croal discusses the evolving landscape of pathology in the UK, the challenges and opportunities, and what's next.

A new study highlights the risks of atopic dermatitis flare-ups after discontinuing dupilumab and the likelihood of restarting treatment.